AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8462190 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate (TU)
Number of subjects: 50
Study 8462190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3942703 — intervention group
Group type: EXPERIMENTAL
Intervention: In-out urethral catheter
Number of subjects: 50
Study 3942703 — intervention group
Group type: COMPARATOR
Intervention: Indwelling urethral catheter
Number of subjects: 50
Study 3942703 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 29160598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 366
Study 29160598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 27525817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ma-Pi diet
Number of subjects: 40
Study 27525817 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study 27525817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24950720 — intervention group
Group type: EXPERIMENTAL
Intervention: AirSeal (group A)
Number of subjects: 182
Study 24950720 — intervention group
Group type: COMPARATOR
Intervention: Standard CO₂ pressure insufflator (group S)
Number of subjects: 182
Study 22378321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous and postoperative oral clindamycin for 7 days
Number of subjects: 120
Study 22378321 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 120
Study 20360919 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (Group I)
Number of subjects: 2
Study 20360919 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedures for abdominal wall hernia (Group II)
Number of subjects: 2
Study 18599520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 18599520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15682483 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM (lamivudine) taken by 10 patients with YMDD mutations
Number of subjects: 104
Study 15682483 — intervention group
Group type: COMPARATOR
Intervention: YMDD mutations in patients with chronic hepatitis B
Number of subjects: 104
Study 15682483 — intervention group
Group type: COMPARATOR
Intervention: HBV DNA level
Number of subjects: 104
Study 15682483 — intervention group
Group type: COMPARATOR
Intervention: HBeAg positive and negative cases
Number of subjects: 104
Study 12430637 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention involving home visits by outreach workers and group meetings in neighborhood settings.
Number of subjects: 370
Study 12430637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 370
Study 10598660 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-980 at 3.5 mg/m2/day for 3 days (continuous intravenous infusion)
Number of subjects: 33
Study 10598660 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-980 at 4.2 mg/m2/day with G-CSF (for brain tumor patients)
Number of subjects: 33
Study 10598660 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-980 at 5 mg/m2/day with G-CSF (for solid tumor patients)
Number of subjects: 33
Study 10598660 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-980 at 5 mg/m2/day regimen
Number of subjects: 33
Study 10598660 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-980
Number of subjects: 33
Study 8773913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding time
Number of subjects: 80
Study 8773913 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous bleeding, liver failure, and variceal size
Number of subjects: 80
Study 8773913 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of liver failure and variceal size
Number of subjects: 80
Study 8773913 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 80
Study 1425821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy (Group 1)
Number of subjects: 702
Study 1425821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination of bromocriptine and levodopa (Group 2A)
Number of subjects: 702
Study 1425821 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone (Group 2B)
Number of subjects: 702
Study 1425821 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 702
Study 6539877 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil HCl
Number of subjects: 0
Study 6539877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31651453 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 3071
Study 31651453 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 3071
Study 30021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 ng/mL (group R2)
Number of subjects: 120
Study 30021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 ng/mL (group R4)
Number of subjects: 120
Study 30021625 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 6 ng/mL (group R6)
Number of subjects: 120
Study 26543061 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated functional appliance (PFA)
Number of subjects: 97
Study 26543061 — intervention group
Group type: COMPARATOR
Intervention: Slightly modified Andresen activator (AA)
Number of subjects: 97
Study 26543061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PFA and AA
Number of subjects: 97
Study 24485052 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable screws
Number of subjects: 54
Study 24485052 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal plates
Number of subjects: 54
Study 22708521 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervising for Home Safety program (content focused on child‐injury risks and supervision needs)
Number of subjects: 0
Study 22708521 — intervention group
Group type: COMPARATOR
Intervention: Control group (content focused on child nutrition and exercise)
Number of subjects: 0
Study 20375791 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 E6 European variants
Number of subjects: 106
Study 20375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed variants of HPV-16 infections
Number of subjects: 106
Study 18586813 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme (physiotherapy, occupational therapy, physical education)
Number of subjects: 54
Study 18586813 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist alone
Number of subjects: 54
Study 18586813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 18586813 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme
Number of subjects: 54
Study 15704053 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times daily
Number of subjects: 107
Study 15704053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 11805349 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐adrenaline (0.1ml/kg/dose in 1 in 10,000 solution)
Number of subjects: 91
Study 11805349 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.1mg/kg/dose)
Number of subjects: 91
Study 10369063 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention (RP)
Number of subjects: 132
Study 10369063 — intervention group
Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 132
Study 8749227 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 60
Study 8749227 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin + Steroid
Number of subjects: 60
Study 8749227 — intervention group
Group type: COMPARATOR
Intervention: Steroid
Number of subjects: 60
Study 1386825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil containing eicosapentaenoic acid (4.1 g/day) and docosahexaenoic acid (3.6 g/day)
Number of subjects: 20
Study 1386825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6837242 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelatine
Number of subjects: 132
Study 6837242 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran
Number of subjects: 132
Study 6837242 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (mean molecular weight 40,000 or 125,000)
Number of subjects: 132
Study 6837242 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution and glucose
Number of subjects: 132
Study 30644740 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus sinensis cv. 'Cara Cara' orange juice (500 mL daily)
Number of subjects: 0
Study 30644740 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus sinensis cv. 'Bahia' orange juice (500 mL daily)
Number of subjects: 0
Study 30644740 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 0
Study 29336387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg loading dose over 15 minutes, followed by 0.5 mcg/kg/h maintenance infusion for 2 hours)
Number of subjects: 60
Study 29336387 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same volume as dexmedetomidine)
Number of subjects: 60
Study 26553461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional support
Number of subjects: 95
Study 26553461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multidisciplinary nutritional support)
Number of subjects: 95
Study 24629408 — intervention group
Group type: EXPERIMENTAL
Intervention: T1W (type 1 diabetes with neuropathy)
Number of subjects: 396
Study 24629408 — intervention group
Group type: EXPERIMENTAL
Intervention: T1WO (type 1 diabetes without neuropathy)
Number of subjects: 396
Study 24629408 — intervention group
Group type: COMPARATOR
Intervention: Controls (without diabetes or neuropathy)
Number of subjects: 396
Study 22344576 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks plus MTX
Number of subjects: 247
Study 22344576 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 247
Study 19643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic blood-flow control during CPB
Number of subjects: 100
Study 19643620 — intervention group
Group type: COMPARATOR
Intervention: Static blood-flow control during CPB
Number of subjects: 100
Study 17957910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (PM) 50 mg daily, Group A
Number of subjects: 60
Study 17957910 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily with/without medroxyprogesterone acetate (MPA) 2.5 mg, Group B
Number of subjects: 60
Study 17957910 — intervention group
Group type: COMPARATOR
Intervention: Both PM and CEE with/without MPA
Number of subjects: 60
Study 16360062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential cardiac resynchronization therapy (CRT) for six months
Number of subjects: 422
Study 16360062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential cardiac resynchronization therapy (CRT)
Number of subjects: 422
Study 16360062 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous cardiac resynchronization therapy (CRT)
Number of subjects: 422
Study 12463580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia with selective factor Xa inhibitor fondaparinux
Number of subjects: 0
Study 12463580 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 10438081 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐to‐one nurse labor support
Number of subjects: 100
Study 10438081 — intervention group
Group type: COMPARATOR
Intervention: Usual intrapartum nursing care
Number of subjects: 100
Study 7503052 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal air monitor
Number of subjects: 0
Study 7503052 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cotinine
Number of subjects: 0
Study 7503052 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire
Number of subjects: 0
Study 7503052 — intervention group
Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 0
Study 7503052 — intervention group
Group type: EXPERIMENTAL
Intervention: Air nicotine
Number of subjects: 0
Study 2338698 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg per day (n = 17)
Number of subjects: 35
Study 2338698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg daily (n = 18)
Number of subjects: 35
Study 6102360 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg and 2 mg)
Number of subjects: 12
Study 6102360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31136460 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict posturing and bilateral patching overnight (Treatment A)
Number of subjects: 80
Study 31136460 — intervention group
Group type: COMPARATOR
Intervention: Posturing alone (Treatment B)
Number of subjects: 80
Study 31634001 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingshu Granules
Number of subjects: 480
Study 31634001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 28681742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-level electrical stimulation (SES) applied to bilateral masseter muscles
Number of subjects: 98
Study 28681742 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 98
Study 26525849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150
Study 26525849 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150
Study 26525849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150
Study 25019968 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic flushing with pronase (50 mL of water, pronase, sodium bicarbonate, and DMPS)
Number of subjects: 198
Study 25019968 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic flushing with water and dimethylpolysiloxane (DMPS; control group)
Number of subjects: 198
Study 22832859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 0
Study 22832859 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride (Control)
Number of subjects: 0
Study 19236805 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-phase RIAC (preoperative combined with postoperative RIAC)
Number of subjects: 100
Study 19236805 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RIAC
Number of subjects: 100
Study 19236805 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-phase RIAC
Number of subjects: 100
Study 17765048 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic regimens (7 days or less)
Number of subjects: 2796
Study 17765048 — intervention group
Group type: COMPARATOR
Intervention: Extended-course antibiotic regimens (>7 days)
Number of subjects: 2796
Study 15666519 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative shaving of the pubic region
Number of subjects: 300
Study 15666519 — intervention group
Group type: COMPARATOR
Intervention: No preoperative shaving of the pubic region
Number of subjects: 300
Study 12351249 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.83 micro g. kg(‐1). min(‐1) (Group R)
Number of subjects: 77
Study 12351249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, small dose, at 12 micro g/kg (Group FLD)
Number of subjects: 77
Study 12351249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, moderate dose, at 24 micro g/kg (Group FMD)
Number of subjects: 77
Study 12351249 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (Group R) compared to Fentanyl (Group FLD)
Number of subjects: 77
Study 9832574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 parts per million)
Number of subjects: 24
Study 9832574 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 24
Study 8137928 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g orally)
Number of subjects: 16
Study 8137928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2733576 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose solution
Number of subjects: 12
Study 2733576 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sucrose solution
Number of subjects: 12
Study 2733576 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% fructose solution
Number of subjects: 12
Study 786825 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose neurotropic vitamins (Neurotrat forte)
Number of subjects: 0
Study 786825 — intervention group
Group type: COMPARATOR
Intervention: Analgesic treatment
Number of subjects: 0
Study 31733182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg) plus aspirin (75 to 100 mg) once daily
Number of subjects: 231
Study 31733182 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg) plus aspirin (75 to 100 mg) once daily
Number of subjects: 231
Study 30566230 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0
Study 30566230 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3 control group
Number of subjects: 0
Study 28222553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-afferent sensory input (DASI) group underwent ETFES with action observation training for 4 weeks (20 min/d, 5 d/wk)
Number of subjects: 18
Study 28222553 — intervention group
Group type: COMPARATOR
Intervention: Functional electric stimulation (FES) in control group for the same duration
Number of subjects: 18
Study 26223668 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) without pretreatment
Number of subjects: 560
Study 26223668 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 560
Study 23025465 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative message (personal testimonial)
Number of subjects: 233
Study 23025465 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐narrative cognitive message (factual risk information using cognitive‐laden words)
Number of subjects: 233
Study 23025465 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐narrative affective message (factual risk information using affective‐laden words)
Number of subjects: 233
Study 23025465 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative message
Number of subjects: 233
Study 21725249 — intervention group
Group type: EXPERIMENTAL
Intervention: couple-based risk reduction
Number of subjects: 564
Study 21725249 — intervention group
Group type: EXPERIMENTAL
Intervention: individual-based HIV risk reduction
Number of subjects: 564
Study 21725249 — intervention group
Group type: COMPARATOR
Intervention: couple-based wellness promotion
Number of subjects: 564
Study 20329690 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel regimen (0.75 mg taken twice in 12-hour intervals within 72 hours after unprotected intercourse)
Number of subjects: 122
Study 20329690 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe method (two HD contraceptive pills)
Number of subjects: 122
Study 16505658 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.052+/‐0.009 microg/kg/min)
Number of subjects: 10
Study 16505658 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.50+/‐0.22 microg/kg/min)
Number of subjects: 10
Study 15047681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato puree supplementation (96 g/day for three weeks)
Number of subjects: 20
Study 15047681 — intervention group
Group type: COMPARATOR
Intervention: Avoidance of tomato-product-rich foods for three weeks
Number of subjects: 20
Study 15047681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato puree supplementation
Number of subjects: 20
Study 15047681 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total antioxidant capacity
Number of subjects: 20
Study 11265439 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch distraction
Number of subjects: 105
Study 11265439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble-blowing distraction
Number of subjects: 105
Study 11265439 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study 9306898 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin 0.5%
Number of subjects: 315
Study 9306898 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin 2.0%
Number of subjects: 315
Study 9306898 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin 0.5%
Number of subjects: 315
Study 8392150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (SC, 6 mg; three attacks)
Number of subjects: 120
Study 8392150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one attack)
Number of subjects: 120
Study 3310570 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 0
Study 3310570 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker
Number of subjects: 0
Study 3310570 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback relaxation
Number of subjects: 0
Study 3310570 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of smoking and serum cholesterol
Number of subjects: 0
Study 30384381 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided treatment allocation (G‐allele carriers receiving naltrexone)
Number of subjects: 0
Study 30384381 — intervention group
Group type: COMPARATOR
Intervention: Standard care (random treatment allocation to acamprosate or naltrexone)
Number of subjects: 0
Study 27743738 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine Serous Carcinoma (USC)
Number of subjects: 753
Study 27743738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Cell Carcinoma (CC)
Number of subjects: 753
Study 27743738 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinosarcoma (CS)
Number of subjects: 753
Study 27743738 — intervention group
Group type: COMPARATOR
Intervention: Grade 3 Endometrioid Adenocarcinoma (ENDO)
Number of subjects: 753
Study 24614165 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART regimens including zidovudine or stavudine plus lamivudine, plus nevirapine or efavirenz
Number of subjects: 321